C3 and dry age related macular degeneration: To date, there is still no commonly used treatment for dry AMD in daily clinical practice, although the complement C3 inhibitor pegcetacoplan has been recently reported to reduce the growth of geographic atrophy in patients with dry AMD [22–24].